price
SR
NASDAQ · SRPT
Sarepta Therapeutics, Inc.
Healthcare · Biotechnology
$19.76
Down-$0.96 (-4.63%)
Updated Sep 17, 2026, 2:38 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.13B
- P/E ratio
- -7.89
- Dividend yield
- 0.00%
- 52-week range
- $14.68 – $23.85
- Volume
- 2.51M
- Avg. volume
- 5.43M
Price performance
SRPT price history
1M range · 20 trading sessions · Daily adjusted prices
SRPT closed at $19.76 after 20 trading sessions, up 0.15% for the selected period.
- Last close
- $19.76
- Period change
- +0.15%
- Period low
- $18.13
- Period high
- $23.21
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $20.68 | $20.89 | $19.72 | $19.76 | 2.51M |
| Sep 15, 2026 | $20.81 | $21.06 | $20.29 | $20.72 | 2.53M |
| Sep 14, 2026 | $20.55 | $21.40 | $20.38 | $20.92 | 2.19M |
| Sep 11, 2026 | $20.76 | $21.10 | $20.29 | $20.45 | 1.81M |
| Sep 10, 2026 | $22.02 | $22.02 | $20.28 | $20.52 | 2.2M |
| Sep 9, 2026 | $20.805 | $23.22 | $20.63 | $22.02 | 4.17M |
| Sep 8, 2026 | $19.86 | $21.32 | $19.51 | $20.94 | 6.24M |
| Sep 4, 2026 | $22.58 | $22.645 | $21.98 | $22.50 | 2.96M |
| Sep 3, 2026 | $23.15 | $23.34 | $22.42 | $22.99 | 2.77M |
| Sep 2, 2026 | $21.33 | $23.62 | $21.33 | $23.21 | 4.81M |
| Sep 1, 2026 | $20.88 | $21.82 | $20.5451 | $21.33 | 2.62M |
| Aug 31, 2026 | $20.56 | $21.16 | $20.1821 | $21.03 | 2.66M |
| Aug 28, 2026 | $21.49 | $22.58 | $20.83 | $20.86 | 3.61M |
| Aug 27, 2026 | $19.35 | $22.59 | $18.77 | $21.59 | 7.92M |
| Aug 26, 2026 | $18.74 | $19.48 | $18.31 | $19.46 | 2.41M |
| Aug 25, 2026 | $18.42 | $19.045 | $18.19 | $18.92 | 1.7M |
| Aug 24, 2026 | $18.53 | $18.705 | $17.90 | $18.13 | 1.38M |
| Aug 21, 2026 | $19.39 | $19.73 | $18.66 | $18.79 | 1.67M |
| Aug 20, 2026 | $19.42 | $19.95 | $18.59 | $19.22 | 2.91M |
| Aug 19, 2026 | $18.74 | $20.19 | $18.74 | $19.73 | 4.94M |
Latest SRPT news
The latest Smart Investors Daily articles mentioning SRPT.
Stock researchCompany · Financials
Loading stock research…

